Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed) | PAR 19 293

Opportunity Information: Apply for PAR 19 293

The NIH funding opportunity PAR 19 293, titled "Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)," supports early-stage, exploratory research aimed at clarifying how genes and environmental exposures work together to influence human health and disease. The core purpose is to move beyond purely observational associations by enabling more direct, mechanistic testing of gene-environment interactions. Rather than focusing on large human epidemiology projects or whole-animal in vivo studies alone, the program emphasizes the creation or refinement of experimental systems that can model gene-environment interplay in a controlled and repeatable way, especially for conditions relevant to dental, oral, and craniofacial biology, while also allowing relevance to other diseases and conditions that fit the program goals.

The FOA is jointly associated with two NIH institutes: the National Institute of Dental and Craniofacial Research (NIDCR) and the National Institute of Environmental Health Sciences (NIEHS). That pairing reflects the intent to bring environmental health science concepts and tools into closer contact with oral and craniofacial research questions. Projects are expected to develop novel, robust, and broadly useful platforms or model systems that complement what can be learned from human population data or standard in vivo experiments. In practice, this can include innovative in vitro or ex vivo systems, engineered cellular or tissue models, organoids, microphysiological systems, advanced co-culture approaches, exposure modeling systems, or other experimental setups designed specifically to test how defined environmental factors interact with genetic variation or genetic perturbations to drive biological outcomes. The emphasis is on tools and systems that enable mechanistic investigation, meaning the ability to probe pathways, causal chains, and biological processes rather than only describing correlations.

This announcement uses the NIH R21 mechanism, which is intended for exploratory and developmental work. The listed award ceiling is $200,000, consistent with the R21 focus on proof-of-concept development, feasibility demonstration, and generation of foundational data that could support larger future studies. The FOA explicitly states "Clinical Trial Not Allowed," which means applications should not propose prospective clinical intervention studies in humans that meet NIH's definition of a clinical trial. The work should stay in the realm of experimental system development and mechanistic research approaches that are complementary to, but not themselves, clinical trials.

A wide range of applicants are eligible. Eligible domestic applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. For international involvement, the announcement draws an important distinction: non-U.S. institutions (foreign institutions) are not eligible to apply as the primary applicant organization, but non-U.S. components of U.S. organizations may participate, and foreign components, as defined in the NIH Grants Policy Statement, are allowed. In other words, the application must be led by an eligible U.S.-based applicant organization, but it can include certain types of international collaboration or foreign components when justified and consistent with NIH policy.

Administratively, the opportunity is categorized as a discretionary grant under the broad federal activity area of environment, health, income security, and social services, and it is associated with CFDA numbers 93.113, 93.121, and 93.865. The opportunity was created on 2019-06-05, and the original closing date shown in the source data is 2022-09-07, indicating the provided record reflects an earlier cycle or set of due dates. Anyone considering applying would typically confirm the current availability and due dates on the official NIH posting, since NIH FOAs can be reissued, extended, or closed over time.

Overall, the program is best read as an invitation to build the kinds of experimental platforms needed to rigorously test how specific environmental exposures (chemical, physical, microbial, nutritional, behavioral, or other relevant factors) interact with genetic background or gene regulation to affect biological systems involved in oral, dental, and craniofacial health, with spillover relevance to other diseases and conditions. The most competitive projects are likely to be those that deliver a clear, mechanistically oriented experimental strategy, show that the system is robust and reproducible, and demonstrate how the resulting approach will enable questions about gene-environment interplay that are hard or impossible to answer using only human epidemiology or conventional in vivo studies.

• The National Institutes of Health in the environment, health, income security and social services sector is offering a public funding opportunity titled "Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.121, 93.865.
• This funding opportunity was created on 2019-06-05.
• Applicants must submit their applications by 2022-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 19 293

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: